BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/2/2026 7:26:01 AM | Browse: 4 | Download: 0
 |
Received |
|
2025-09-16 09:21 |
|
Peer-Review Started |
|
2025-09-16 09:21 |
|
First Decision by Editorial Office Director |
|
2025-10-13 09:07 |
|
Return for Revision |
|
2025-10-13 09:07 |
|
Revised |
|
2025-10-31 06:43 |
|
Publication Fee Transferred |
|
2025-11-04 03:31 |
|
Second Decision by Editor |
|
2025-12-11 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-11 11:12 |
|
Articles in Press |
|
2025-12-11 11:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 01:45 |
|
Publish the Manuscript Online |
|
2026-02-02 07:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Yuan Zhang, Rui-Qian Sun, Qi Min, Yu-Qi Zhu, Shu-Kui Qin and Qing-Long Guo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mei-Yuan Zhang, Intensive Care Unit, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine/Shanghai Key Laboratory of Embryo Original Disease, Shanghai Municipal Key Clinical Specialty, No. 1567 Jinqian Road, Fengxian District, Shanghai 201499, China. zhangmeiyuan1972@163.com |
| Key Words |
Hepatocellular carcinoma; Oroxylin A; Donafenib; Combination therapy; Xenograft tumor; TP53 signaling pathway |
| Core Tip |
This study demonstrates that the combination of oroxylin A and donafenib exerts a potent synergistic antitumor effect against hepatocellular carcinoma in vitro and in vivo. Mechanistically, this synergy is achieved through the convergent activation of the tumor-suppressive tumor protein p53 signaling pathway. This work provides a novel and effective therapeutic strategy for hepatocellular carcinoma. |
| Publish Date |
2026-02-02 07:26 |
| Citation |
Zhang MY, Sun RQ, Min Q, Zhu YQ, Qin SK, Guo QL. Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation. World J Gastroenterol 2026; 32(6): 113529 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i6/113529.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i6.113529 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
